fda decision: roflumilast (arq-151) by arcutis biotherapeutics (on 2026-01-01)
Conditional / Accelerated Approval
fda decision: roflumilast (arq-151) by arcutis biotherapeutics (on 2026-01-01). Best Yes near 6¢ across 1 platform. Live cross-platform prices. Not financial…
Best Yes: 6¢ · Best No: 100¢ · 1 platform
- Kalshi: Yes 6¢ / No 100¢
LIVE
Conditional / Accelerated Approval
Volume
$332
$19 24h
Platforms
1
Cross-platform pricing
Resolution
Resolves Jul 1, 2026
~15 days left
Category
Economics
Yes
6¢
Kalshi
No
100¢
Kalshi
Opens on best-price platform
Compare & Trade
1 platform
Price History
Loading…
About This Market
If the FDA's decision on Roflumilast (ARQ-151) by Arcutis Biotherapeutics in June 2026 is Conditional / Accelerated Approval before Jul 1, 2026, the market resolves to Yes.
Market Details
ResolutionResolves Jul 1, 2026
Time Left15 days
Status● Active
CategoryEconomics
Yes
6¢
Kalshi
Payout 16.7x
No
100¢
Kalshi
Payout 1.0x
Opens on best-price platform
Compare & Trade
1 platformSign in to join the discussion
Sign In